Sparrow Pharma

Sparrow Pharmaceuticals develops an oral HSD1 inhibitor to reduce cortisol for treating Cushing’s disease and treatment-resistant type 2 diabetes.
Domain
Healthcare
Status
Current Private Investment
Stage of Initial Investment
Series B
Initial Investment Year
2025